Ceftriaxone protects against tobramycin nephrotoxicity

Area of Science:

• Pharmacology
• Nephrology
• Toxicology

Background:

• Aminoglycosides like tobramycin are essential antibiotics but can cause nephrotoxicity.
• Ceftriaxone is a third-generation cephalosporin with a broad spectrum of activity.
• Investigating the potential protective effects of ceftriaxone against tobramycin-induced kidney damage is crucial for optimizing antibiotic use.

Purpose of the Study:

• To evaluate the impact of ceftriaxone on tobramycin-induced nephrotoxicity in a rat model.
• To assess the effects of combined ceftriaxone and tobramycin treatment on renal function and biomarkers of kidney injury.

Main Methods:

• Female Sprague-Dawley rats were administered saline, ceftriaxone, tobramycin (40 or 60 mg/kg), or a combination of ceftriaxone and tobramycin for 4 or 10 days.
• Serum creatinine levels, renal tobramycin accumulation, sphingomyelinase activity, [3H]thymidine incorporation, and urinary beta-galactosidase excretion were measured.
• Renal histology was examined to assess cellular alterations and signs of toxicity.

Main Results:

• Tobramycin alone (60 mg/kg for 10 days) significantly increased serum creatinine compared to controls and the combination group.
• Ceftriaxone reduced renal accumulation of tobramycin and mitigated the inhibition of sphingomyelinase activity caused by tobramycin.
• The combination therapy led to lower [3H]thymidine incorporation and reduced urinary beta-galactosidase excretion, indicating less kidney damage.
• Histological analysis showed reduced signs of tobramycin nephrotoxicity in rats treated with the combination therapy.

Conclusions:

• Ceftriaxone demonstrates a protective effect against tobramycin-induced nephrotoxicity in rats.
• The combination of ceftriaxone and tobramycin may reduce kidney damage by decreasing tobramycin accumulation and preserving renal cell function.
• This finding suggests a potential therapeutic strategy to mitigate aminoglycoside-induced kidney injury.